Ambalal Sarabhai Enterprises Ltd vs Concord Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 33.09 as of 08 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Concord Drugs Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 243 Cr while Market cap of Concord Drugs Ltd is 110 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd?

As of May 8, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.79. On the other hand, Concord Drugs Ltd stock price is INR ₹83.95.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Concord Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.